1] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France [2] INSERM CRNCA UMR 892, Université de Nantes, Faculté de Médecine, Nantes, France.
Leukemia. 2013 Nov;27(11):2113-7. doi: 10.1038/leu.2013.170. Epub 2013 Jun 11.
This retrospective report compared the results of graft source on outcome after allogeneic stem cell transplantation (allo-SCT) in patients with hematologic malignancies receiving a reduced intensity conditioning (RIC) regimen. A total of 152 patients received either a RIC allo-SCT using a 9/10 mismatched unrelated donor (MisMUD, n=42) or a double unrelated umbilical cord blood (dUCB, n=110) graft. With a median follow-up of 30.3 months, the cumulative incidence of non-relapse mortality was 26% in the dUCB group versus 24% in the MisMUD group (P=0.95). Grade 3-4 acute graft-versus-host disease (GVHD) incidence was 19.7% in the dUCB group versus 21.4% in the MisMUD group (P=0.83). The cumulative incidence of extensive chronic GVHD at 2 years was 6.4% in the dUCB group versus 21.4% in the MisMUD group (P=0.02). The Kaplan-Meier estimate of overall survival at 2 years was comparable between both groups (52.3% (95% confidence interval (CI), 42.1-61.5%) in the dUCB group versus 47.9% (95% CI, 31.6-62.4%) in the MisMUD group, P=0.55). Progression-free survival at 2 years was 43.3% (95% CI, 33.7-52.5%) in the dUCB group versus 38.3% (95% CI, 23.2-53.3%) in the MisMUD group (P=0.55). These data suggest that dUCB is a valid alternative graft source with significantly less chronic GVHD compared with MisMUD in the setting of RIC allo-SCT.
本回顾性报告比较了接受低强度预处理(RIC)方案的血液恶性肿瘤患者,异体干细胞移植(allo-SCT)后移植物来源对结果的影响。共有 152 名患者接受了RIC allo-SCT,其中 42 名患者使用 9/10 错配无关供体(MisMUD),110 名患者使用双份无关脐血(dUCB)移植物。中位随访 30.3 个月后,dUCB 组非复发死亡率累积发生率为 26%,MisMUD 组为 24%(P=0.95)。dUCB 组 3-4 级急性移植物抗宿主病(GVHD)发生率为 19.7%,MisMUD 组为 21.4%(P=0.83)。dUCB 组 2 年广泛慢性 GVHD 的累积发生率为 6.4%,MisMUD 组为 21.4%(P=0.02)。两组 2 年总生存率的 Kaplan-Meier 估计值相当(dUCB 组为 52.3%(95%置信区间(CI),42.1-61.5%),MisMUD 组为 47.9%(95% CI,31.6-62.4%),P=0.55)。dUCB 组 2 年无进展生存率为 43.3%(95% CI,33.7-52.5%),MisMUD 组为 38.3%(95% CI,23.2-53.3%)(P=0.55)。这些数据表明,与 MisMUD 相比,dUCB 是 RIC allo-SCT 中一种有效的替代移植物来源,其慢性 GVHD 明显较少。